TDC
ALIM

Thompson Davis & Co’s Alimera Sciences ALIM Stock Holding History

Thompson Davis & Co’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$40K Buy
+2,735
New +$41.6K 0.09% 241

Other funds holding ALIM

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

Thompson Davis & Co's ALIM Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Alimera Sciences (ALIM) in Q3 2018: 2,735 shares worth $40K. The stake represents 0.09% of the portfolio and ranks #241 among its holdings.

43 funds tracked by Wall St. Rank hold ALIM as of Q3 2018.

  • Thompson Davis & Co held 2,735 shares of Alimera Sciences worth $40K as of Q3 2018.
  • Alimera Sciences was a new Thompson Davis & Co position in Q3 2018.
  • Alimera Sciences made up 0.09% of Thompson Davis & Co's portfolio in Q3 2018, its #241 holding.
  • 43 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.